ADIENNE’s Management team is based in Lugano (Switzerland) and it is in charge of the day-to-day management of the company’s business.
Antonio Francesco Di Naro (born in 1966) is President. He holds a doctor in chemistry and pharmaceutical technologies and developed two transplantation products (Thymoglobuline and Celsior). He has more than 20 years’ experience in the development of orphan drugs from reasearch to commercialization. He began his career as a teacher at vocational schools of Bergamo (Italy) from 1986 to 1989. From 1989 to 1992, he worked as researcher at the Pharmacology Laboratory of Research Institute Mario Negri (Italy). He joined Janssen Pharmaceutical Spa (Italy) where he was employed as a sales manager from 1992 to 1994. From 1994 to 1996 he moved to Pasteur Mérieux S.r.l. (Italy) where he worked as general manager. From 1996 to 1998, he began to work as general manager at IMTIX (Italy) and Corporate Director South Europe at IMTIX (France). From 1998 to 2003 he joined SangStat, where he was active in different functions (CEO and general manager; vice president Europe and International). From 2003 to 2004, he was employed as a vice president Europe and International of Genzyme. From 2004, he was co-founder of OPi Pharma and he founded DICRAM SA, ADIENNE S.r.l., ADIENNE SL, ADIENNE SA and the Company.
Alessandra Berardi (born in 1964) graduated in Foreign Languages and Literature from the University of Venice (Russian and English).
After various professional experiences as a free-lance interpreter and translator, she joined ADIENNE in 2005 as HR Manager and has been managing the Corporate HR Offices since 2014.
Enrico Paroni (born in 1977) is ADIENNE Pharma & Biotech General Manager. He holds a doctor in chemistry and pharmaceutical technologies. He has more than 15 years’ experience in the formulation, process development and manufacturing of liquid and lyophilized injectable products. He began his carrier in 2003 at AstraZeneca (Italy) where he covered several positions from Computer and Process Validation to Project Leader. From 2009 to 2011 he was Project Manager at Corden Pharma (Italy). From 2011 until 2015 he worked as R&D/NPI Manager at Corden Pharma (Italy) and further as Aseptic Operations Manager and NPI until 2018. He joined ADIENNE in July 2018.
Federico Sanvito (born in 1966) is Chief Manufacturing Officer of ADIENNE and is also acting as the Company’s General Manager for Italy. He obtained an advanced degreee in Engineering at Politecnico di Milano in 1994 and has an over 20 years working experience in pharmaceutical manufacturing as Engineering Director at Bausch & Lomb and as Engineering Manager at AstraZeneca.
Francesc Corpas Lara (born in 1969) is ADIENNE’s Chief Commercial Officer. He began his career at Parke Davis and later at Aventis Spain where he developed several projects; the latest project was developed in the area of pharmaceuticals for severe and rare diseases. He also held several executive positions at SangStat Spain SL, an US biopharmaceutical company listed at the NASDAQ. As General Manager SangStat Spain SL., Francesc has contributed to solving the therapeutic and research needs in the area of transplant and has also executed several partnerships with pharmaceutical companies. He joined the company in 2005.
Marco Sardella (born in 1979) is Chief Pharmacovigilance Officer and European Qualified Person for Pharmacovigilance (EEA QPPV) of ADIENNE. In this function, he is globally responsible for the safety of products under investigation and/or available on the markets. He heads the Pharmacovigilance and Risk Management teams. He has a degree in Pharmaceutical Chemistry and Technologies from the University of Sassari (Italy). Previously, he was acting as EEA QPPV and Head of Safety for Gentium SpA (Jazz Pharmaceuticals). He joined the company in 2015.
Michela Spinelli (born in 1983) is Chief Scientific Officer. She holds a PhD in Industrial Biotechnology Pharmacogenomics from the University of Milan-Bicocca (Italy) and she has 15 years’ experience in cancer academic research.
From 2009 to 2010 she worked as researcher at Kimmel Cancer Center, Department of Urology (Philadelphia, USA). From 2010 to 2011 she moved as researcher to the San Raffaele Hospital, Department of Immunotherapy of Solid Tumors (Italy). From 2012 to 2016 she worked as post-doc at UNIMI-Bicocca (Italy) in the field of cellular biology, development of biological assay and drug discovery. She joined ADIENNE in 2016 and today she is responsible for all research and development programmes.
Silvana Minoretti (born in 1963) is a member of the Board of Directors. She is a chartered financial analyst CFA®, certified accountant and a tax law expert. Furthermore, Silvana Minoretti is a member of the grand council of the Canton of Ticino, Tax commissioner, member of the board of the supervisory authority for trust service providers of Canton Ticino and member of the board of Pentagram Wealth Management SA. Additionally, Silvana Minoretti is president of the board of directors of Smaril SA and member of the board of directors of Pawin SA Asset Management.
Silvia Nosari (born in 1981) is ADIENNE’s Chief Regulatory Affairs Officer. She graduated from the University of Milan (Italy) in Industrial Biotechnology Pharmacogenomics. Afterwards, she joined the Milan-based Istituto Mario Negri as research scientist, conducting genetic research in the field of rare diseases. She joined the company in 2006 as R&D Manager and is heading the Regulatory Affairs since 2015.